-
Loading metrics
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
- Michael E. Goldberg,
-
Meagan Montesion,
Roles Investigation, Writing – review & editing
Affiliation Foundation Medicine Inc., Cambridge, Massachusetts, United States of America
⨯ - Lauren Young,
-
James Suh,
Roles Data curation, Investigation
Current address: Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Washington D.C., United States of America
Affiliation Foundation Medicine Inc., Cambridge, Massachusetts, United States of America
⨯ - Joel Greenbowe,
- Mark Kennedy,
- Giuseppe Giaccone,
- Wallace L. Akerley,
- Afshin Dowlati,
- Benjamin C. Creelan,
- James K. Hicks,
- Paul J. Hesketh,
- Karen L. Kelly,
- Jonathan W. Riess,
- Vincent A. Miller,
- Philip J. Stephens,
- Garrett M. Frampton,
- Siraj Ali,
- Jeffrey P. Gregg ,
- [ ... ],
-
Lee A. Albacker
Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing
* E-mail: lalbacker@foundationmedicine.com (LAA); jpgregg@ucdavis.edu (JPG)
Affiliation Foundation Medicine Inc., Cambridge, Massachusetts, United States of America
⨯ - [ view all ]
- [ view less ]
http://orcid.org/0000-0001-9155-556X
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
- Michael E. Goldberg,
- Meagan Montesion,
- Lauren Young,
- James Suh,
- Joel Greenbowe,
- Mark Kennedy,
- Giuseppe Giaccone,
- Wallace L. Akerley,
- Afshin Dowlati,
- Benjamin C. Creelan
- Published: November 27, 2018
- https://doi.org/10.1371/journal.pone.0208097